FGF2 and Apert syndrome: The presence of the FGF2 oncogenic variant can be explained because a group of syndromic craniosynostoses, such as Apert syndrome, has been associated with mutations in genes encoding proteins belonging to the same biological pathway, the fibroblast growth factor receptor (FGFR).